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ABSTRACT
In order to study mechanisms underlying selective enzyme release from human leukocytes
during phagocytosis, the effects were studied of compounds which affect microtubule integrity or the accumulation of cyclic nucleotides . Human leukocytes selectively extrude
lysosomal enzymes (,3-glucuronidase) from viable cells during phagocytosis of zymosan or
immune complexes, or upon encounter with immune complexes dispersed along a nonphagocytosable surface such as a millipore filter . In each circumstance, lysosomal enzyme
release was reduced by previous treatment of cells with pharmacological doses of drugs
which disrupt microtubules (e.g. 10-8-10_6 M colchicine) or with agents which affect
accumulation of adenosine 3'5'-monophosphate (cAMP) (e .g . 10_e M cyclic nucleotides
and 2 .8 x 10-4-2.8 X 10_ 6 M prostaglandin E (PGE) and A (PGA) compounds) . Preincubation of cells with 5 µg/ml cytochalasin B resulted in complete inhibition of zymosan
ingestion, but not of adherence of zymosan particles to plasma membranes or selective
enzyme release . In this system, in which enzyme release was independent of particle uptake, preincubation of cells with colchicine, vinblastine, dibutyryl sAMP, or PGE 1 also
reduced extrusion of lysosomal enzymes . When cell suspensions were incubated with membrane-lytic crystals of monosodium urate (MSU), cytoplasmic as well as lysosomal enzymes were released with subsequent death of the cells . However, enzyme release followed
phagocytosis of crystals (as measured by enhanced C-1 oxidation of glucose) and was due
to "perforation from within" of the lysosomal membrane, rather than lysis by crystals of
the plasma membrane. Enzyme release after MSU ingestion was also reduced when cells
were treated with pharmacological doses of the test agents. When cells were killed by
Triton X-100, acting on the plasma membrane, C-1 oxidation of glucose was abolished
and enzyme release could not be inhibited pharmacologically . These observations suggest
that lysosomal enzyme release from human phagocytes can be an active process which
accompanies plasma membrane stimulation, is independent of cell death, and may be
controlled by cyclic nucleotides and agents which affect microtubules .
Although a series of studies has indicated that nisms which account for release from inflammaextracts of leukocyte lysosomes can provoke acute tory cells of such materials is just beginning to
and chronic inflammation in experimental ani- emerge . Four separate circumstances are recogmals (1), a clear definition of discrete mecha- nized under which substances ordinarily se-
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questered within lysosomes may gain access to
the exterior of cells.
One mechanism has been termed "regurgitation during feeding" (2), and may be important
to the propagation of joint inflammation in rheumatoid arthritis . When cells engage in phagocytosis (e .g . leukocytes which engulf immune complexes in the synovial fluid of patients with rheumatoid arthritis) they release a portion of their
lysosomal hydrolases into the surrounding medium . This effect appears due to extrusion of
lysosomal materials from incompletely closed
phagosomes open at their external border to
tissue space while joined at their internal border
with granules discharging acid hydrolases into
the vacuole (phagolysosome) . Under such circumstances lysosomal enzymes are selectively
released to the outside of the cell without necessarily causing cytoplasmic damage. Electronmicroscope images consistent with such a mechanism have in fact been published (3, 4) .
A second mechanism has been called "reverse
endocytosis" (5), and may be pertinent to the
pathogenesis of tissue injury in nephritis, vasculitis, and rheumatoid arthritis . When leukocytes
encounter immune complexes which have been
dispersed along a nonphagocytosable surface
such as a Millipore filter (Millipore Corp ., Bedford, Mass .) or collagen membrane there is
similar, selective release of lysosomal enzymes
directly to the outside of the cell (6, 7) . Enzyme
release may occur when leukocytes are in apposition to immune complexes in a blood vessel
wall, in the glomerular basement membrane, or
when pannus encounters articular cartilage .
Another mechanism for enzyme release ("perforation from within" [8]) occurs when certain
materials gain access to the vacuolar system
wherein they interact with, and finally rupture,
lysosomal membranes . A wave of membrane
damage results with release of cytoplasmic and
lysosomal enzymes followed by cell and tissue
death . The inflammatory episodes of acute gout
appear due to this type of encounter between
leukocytes and crystals of monosodium urate
(MSU) (9) .
Finally, inflammatory substances may leak
from cells simply as a result of cell death due to
plasma membrane injury . A number of animal,
bacterial, and chemical toxins, as well as synthetic detergents may cause such lysis of the outer
cell membrane (10) .
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Since enzyme release under each circumstance
may be crucial to the perpetuation of tissue injury, it may be that reduction of such enzyme release would prove beneficial . The effect on these
four mechanisms of enzyme release was therefore
studied of agents which regulate the secretion of
stored proteins in tissues such as pancreas, salivary gland, and thyroid . Two types of compounds
were studied : those which affect the function of
microtubules and microfilaments, and those
which influence the accumulation within cells of
cyclic nucleotides . The results suggest that selective enzyme release from human phagocytes is
independent of cell death and that pharmacologic agents can reduce lysosomal enzyme release in three of four experimental challenges .
When cells were killed by means of a lethal
injury to the plasma membrane (Triton X-100),
enzyme release could not be inhibited by pharmacologic means .
MATERIALS AND METHODS

Separation of Leukocytes
Leukocytes were obtained from the venous blood
of healthy young men . Blood (40 cms) was drawn
into plastic syringes (60 cm 3 ; Sherwood Medical
Industries, Inc ., Deland, Fla.) previously moistened
with 0.4 ml of heparin (1000 U/ml ; Liquaemin
Sodium®, Organon Inc., West Orange, N. J .) and
containing 8 ml of a 6% dextran solution (average
molecular weight of dextran ; 248,000 ; Pharmachem,
Bethlehem, Pa.) . After gentle mixing, sedimentation
was allowed to proceed in the same syringe for 10-20
min at room temperature . The cell-rich supernatant
was carefully transferred to centrifuge tubes and the
cells were sedimented at 800 rpm (100 g) for 8 min
in an International (Model UV) centrifuge at room
temperature. Supernatant fluid was removed, the
erythrocytes were removed by hypotonic lysis (8
cm3 0 .85% NaCl, add 24 cm 3 distilled water for 30
s, add 8 cm3 2 .6% NaCl), and the leukocytes were
washed once in 0.15 M NaCl and resuspended in
the buffered medium .
Medium
Calcium and magnesium, at final concentrations
of 0.6 and 1 mM respectively, were added to phosphate-buffered saline (Grand Island Biological Co .,
Grand Island, N . Y .) to produce "PiCM", pH 7 .3 .
Leukocyte Suspensions
Cell pellets were resuspended in PiCM to a concentration of 4 X 10 6 leukocytes per ml (83 f 5%
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polymorphonuclear leukocytes . N = 10) . The platelet : leukocyte ratio was 5 :1 . Even in 20-fold excess
platelets contained negligible proportions of total
/9-glucuronidate activity (11) . The remaining cells
were lymphocytes and monocytes which when separated on Hypaque-Ficoll gradients (12) proved to
contain only 1 .6% of the total (3-glucuronidate
activity and 9.4% of the lactate dehydrogenase
(LDH) activity of the lymphocyte/monocyte contaminated polymorphonuclear leukocyte preparation. Portions of cell suspensions (1 .0 ml) were dispensed into 10 X 75 mm plastic test tubes . The
cells were incubated at 37 ° C with appropriate drugs,
autologous serum was added to a concentration of
10%, then cells were exposed to particles. At the
end of experiments, tubes were centrifuged at 2500
rpm (755 g) at 4 °C in a Sorvall centrifuge (Sorvall
Superspeed, Rotor No . SS-1, Ivan Sorvall, Inc .,
Newtown, Conn.) . The cell-free supernatants were
removed for enzyme determination. Cells were fixed
for electron microscopy as previously described (5) .
Cells were also stained for peroxidase by the method
of Graham and Karnovsky (13) .

Viability of Cells
The integrity of leukocytes in the pellets at the
end of experiments was assayed by several techniques. (a) Exclusion of eosin Y : a cell pellet was
diluted in 0.5% eosin Y in saline, mixed, and cells
were counted in a hemocytometer . Nonviable cells
lost their ability to exclude eosin Y and stained pink .
In no instance did the proportion of nonviable cells
exceed 3% (except in studies with MSU and Triton
X-100) . (b) Phagocytosis : the percent of cells capable of phagocytosis (>85%) when zymosan was
added after a 5-h incubation period was no less
than when cells were incubated immediately with
zymosan. (c) LDH determinations : extracellular
escape of cytoplasmic enzymes was taken to indicate cell death. (d) A normal metabolic response
(C-1 oxidation of glucose) to phagocytosis was determined (14) .

Particles
Zymosan particles (Nutritional Biochemicals Corporation, Cleveland, Ohio), measuring 3-5 µm
in diameter, were suspended in saline, boiled,
washed twice, and resuspended (5 mg/ml) in PiCM .
Particle counts were performed with a standard
hemocytometer.

Immune Complexes
Aggregated human y-globulin was prepared from
Cohn Fraction II (courtesy of Dr . Edward C . Franklin) by heating at 63°C for 20 min . The antigen,
present in excess (1 .0 ml of a 1% solution in 0 .15
M NaCl), was added to 5 ml of a high titer (1 :5120)
rheumatoid serum (antibody) and reacted at 4 ° C
for 24 h. The precipitate was washed three times in
0 .15 M NaCl and resuspended in PiCM . The preparation is referred to as rheumatoid factor complex
(RF-algG), or algG/IgM . Protein concentration of
the immune precipitates was adjusted to 100 ug/0 .1
ml .

Enzyme Assays
,Q-glucuronidase was determined at 18 h of incubation with, phenolphthalein glucuronidate as
substrate, as previously described (16) . Readings were
obtained in a Beckman-DB Spectrophotometer
(Beckman Instruments, Inc ., Fullerton, Calif.) at
540 nm . LDH was determined by the method of
Wacker et al. (17), measuring reduction of nicotinamide adenine dinucleotide phosphate (NADP) .
Readings were obtained every minute for 3 min at
340 nm in a Beckman-DU Spectrophotometer .

Enzyme Recovery
Appropriate control experiments performed as
previously described (11) indicated that there was
no preferential degradation of enzyme activity
(/3-glucuronidase or LDH) in resting cells, excluded
the possibility that particles and test compounds
interfered with enzyme assays, and tested for selective
adsorption of enzymes to cells or particles after
their release into the medium . Recovery of enzymes
was unimpaired .

Compounds
Prostaglandins were kindly furnished by Dr . John
Pike, Upjohn Co., Kalamazoo, Mich . ; 2-chloroadenosine (2-CA) compliments of Dr. Colin Bayley,
Cyclo Chemical Corp ., Los Angeles, Calif. ; theophylline : Mann Research Labs, Inc ., New York ;
3'S'-cAMP and dibutyryl 3'5'-cAMP ; Sigma Chemical Co., St . Louis, Mo. ; cytochalasin B : ICI Research Laboratories, Alderley Park, Cheshire, England . Cytochalasin B was dissolved in 0 .1 % dimethylsulfoxide (DMSO) . This concentration of DMSO did
not alter cell viability or morphology .

MSU Crystals
Microcrystalline urate was prepared as described
by McCarty and Faires (15) . Samples of crystals
were ground to produce particles 0 .5-30 µm in
length .

C-1 Oxidation of Glucose
Stimulation of leukocyte hexose monophosphate
shunt activity in response to phagocytosis of particles
was measured utilizing minor modifications of a pre-

ZDRIER, HOFFSTEIN, AND WEISSMANN

Lysosomal Enzyme Release

29

viously described method (14) . 1-ml portions of
leukocyte suspensions containing 2 .4-4 .8 X 10 1
cells/ml in PiCM buffer were added to 25-m1 Erlenmeyer flasks containing 0 .25 ml of autologous serum,
0.25 µCi o-[I- 14C]glucose in 0.5 ml buffer, and either
buffer alone or particles suspended in buffer, to a
final volume of 2 .5 ml . The evolution of 14 C02
measured as counts per minute, by leukocytes incubated with particles compared to 14CO2 evolution
from cells incubated without particles, has been shown
to reflect the degree of phagocytic activity (14) . The
increment of 14002 evolution from cells exposed to
MSU was linear over a dose range of 0 .1 mg/m1-10
mg/ml.

Nonphagocytosable Surface
Millipore filters (Millipore Corp . ; pore diameter
0.22 µm) were soaked overnight in phosphatebuffered saline (PBS), then rinsed . Appropriate concentrations of the aIgG/IgM complex were layered
on the filter surface and allowed to dry . Filters were
washed with PBS before use . Experiments were performed in vessels described by Gerber and Schubert
(18) . Two Plexiglas chambers were separated by the
Millipore filter . The cell suspensions were preincubated in tubes as in the bulk phase experiments, then
transferred to the chamber . The cells were allowed to
settle onto the filter . The two chambers were clamped
tightly together so that none of the cell suspension
leaked around the filter . The bottom chamber re-

mained dry, indicating that medium did not penetrate the filter .
RESULTS

Cells Exposed to Zymosan and to
Immune Complexes in the Bulk Phase
Exposure of human leukocytes to zymosan
or to aIgG/IgM complexes results in the selective
release of lysosomal enzymes with maintenance
of cell viability (11) . The selective nature of the
enzyme release, the kinetics of enzyme release,
and the influence on enzyme release of cell :
particle ratio are all demonstrated in Fig . 1 .
Release of enzyme was maximum after 120 min of
incubation with a particle : cell ratio of 30 :1 .
Although in this experimental system nearly all
phagocytosis occurs in the first 30 min of incubation, further phagocytosis was observed during a
subsequent 30-min period . Release of enzyme
therefore appears to be very closely related to
phagocytosis and not to an event which is significantly delayed . However, when cells are
exposed to smaller numbers of particles (particle :
cell ratio of 3 :1) phagocytosis is completed by
30 min but there is a substantial increment of
selective enzyme release during the following 90
min . Thus, ingestion of large numbers of par-
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ticles induces greater enzyme release earlier and
abolishes the delay in enzyme release observed
with the smaller particle : cell ratio . The kinetics
of enzyme release suggest two possibilities : (a)
formation within cells of phagocytic vacuoles may
stimulate movement of granules to the cell periphery, or (b) phagocytic vacuoles remain open to
the outside during the entire 120-min period .
When cells were incubated with compounds
which increase cellular levels of cAMP or which
interfere with microtubule integrity before their
exposure to zymosan or immune complex, reduction in lysosomal enzyme release was observed (Tables I and II) . cAMP itself had no

effect on extrusion of lysosomal enzymes . However, in combination with theophylline or 2-CA,
both of which inhibit phosphodiesterase, cAMP
caused a considerable reduction in enzyme release . Prostaglandin E 1 (PGE,) also blocked
selective hydrolase release . When theophylline
or 2-CA was added during preincubation with
PGE 1 it acted further to reduce hydrolase release .
Theophylline and 2-CA alone produced a dosedependent reduction in lysosomal enzyme release . Colchicine at a concentration of 10-3 M,
but not at lower concentrations, also reduced
enzyme release (Tables I and II) .
PGE and PGA compounds stimulate the accu-

TABLE I
Inhibition of Enzyme Release from Human Leukocytes Exposed to Zymosan*
Percent of control enzyme release
Compound

Concentration

No.

/3-Glucuronidase

Lactate dehydrogenase

M

None
3'5'-cAMP
Theophylline
2-Chloroadenosine
3'5'-cAMP
+
theophylline
3'5'-cAMP
+
2-chloroadenosine
Dibutyryl cAMP
PGE1
PGE1
+
theophylline
PGE1
+
2-chloroadenosine
Colchicine

10 -3
10-3
10 -3
10 -3
+
10 -3
10 -3
+
10 -3
10 -3
2 .8 X 10 -4
2 .8 X 10-4
+
10-3
2 .8 X 10-4
+
10-3
10-3

10
5
5
5

100 .0
94 .9 t 2 .0
77 .8 t 2 .5t
73 .4 f 4 .5$

100 .0
99 .4 f 1 .1
98 .3 f 0 .6
98 .4 t 0 .9

5

39 .3 f 8 .4$

100 .6 f 1 .7

5

47 .2 t 9 .11

100 .9 t 1 .4

5
5

63 .1 t 4 .7$
67 .4 t 7 .61

98 .9 f 1 .0
101 .2 t 0 .8

5

46 .1 f 3 .8$

100 .8 t 1 .4

5

44 .3 t 4 .2$

101 .6 t 0 .9

6

68 .2 t 4 .1$

98 .8 f 1 .1

Percent of total enzyme release§
/3-Glucuronidase

Resting cells
Cells + zymosan

10
10

4 .7 t 3 .0
22 .4 t 2 .9

Lactate dehydrogenase

1 .8 f 1 .5
2 .1 f 1 .3

* Leukocytes (4 X 10 6 ) incubated with drug for 60 min at 37 ° C, then exposed to zymosan particles for 60 min .
$ Significant at P < 0 .01 vs . control of 100% .
§ Enzyme activity expressed as a percentage of total activity released by 0 .2% Triton
X-100 . Total activity (100%) of f3-glucuronidase was 19 .7 t 2 .7 jug phenolphthalein/
4 X 10 6 leukocyte/h ; lactate dehydrogenase : 1260 f 81 absorbancy units/4 X 10 6
leukocyte .
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TABLE II

Inhibition of Enzyme Release from Human Leukocytes Exposed to Immune Complex in Bulk
Phase*
Percent of control enzyme release
Compound

Concentration

No.

f3-Glucuronidase

Lactate dehydrogenase

M

None
3'5'-CAMP
Theophylline
2-Chloroadenosine
3'5'-cAMP
+
theophylline
Dibutyryl cAMP
PGEI
PGEI
+
theophylline
PGE1
+
2-chloroadenosine
Colchicine

Control

10
3
8
4

100 .0
93 .8 t 1 .7
55 .4 t 5 .31
58 .7 ± 4 .61

3

39 .4 ± 2 .91

99 .6 t 0 .8

7
7

54 .2 f 4 .41
57 .8 ± 8 .61

98 .7 f 1 .1
99 .8 f 0 .6

5

38 .3 f 2 .71

100 .3 t 0 .9

+
10-3

4

35 .8 t 3 .41

100 .9 t 1 .4

10-3

6

60 .1 f 4 .91

101 .0 f 1 .6

10'3
10'3
10'3
10-3
+
10-3
10-3

2 .8 X 10-4
2 .8 X 10-4
+
10-3

100 .0
100 .4 f 0 .9
101 .4 t 1 .0

2 .8 X 10-4

Percent of total enzyme release¢
#-Glucuronidase

Resting cells
Cells + aIgG/IgM

3 .1 f 1 .2
14 .4 f 1 .6

10
10

Lactate dehydrogenase

2 .0 f 0 .9
2 .9 f 1 .0

* Leukocytes (4 X 10 6) incubated with drug for 60 min at 37°C, then exposed to
aIgG/IgM for 120 min .
1 Significant at P < 0 .01 vs . control of 100% .
§ Enzyme activity expressed as a percentage of total activity released by 0 .2c/
, o Triton
X-100 . Total activity (100%) of ,3-glucuronidase was 20 .8 f 1 .7 µg phenolphthalein/
4 X 10 6 leukocyte/h ; lactate dehydrogenase : 1320 t 102 absorbancy units/4 X 10 6
leukocyte .
mulation of cAMP in mixed populations of human
leukocytes whereas prostaglandin F compounds
have little or no effect on cAMP levels (19, 20) .
For example, whereas the concentration of
cAMP in resting cells was 6 pmol/10 7 cells,
incubation of cells with 10-2 M theophylline and
10-6 M PGE 1 raised the level to 18 and 66 pmol,
respectively and the two compounds together
caused an accumulation of 220 pmol/107 cells
(21) . Preincubation of leukocytes with prostaglandin E and A compounds consistently reduced
selective extrusion of lysosomal enzymes from
cells exposed to zymosan . However, pretreatment of cells with the same concentrations of
prostaglandin F 1,9 had little effect on enzyme
release . Prostaglandin F 2a enhanced enzyme
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release by virtue of causing cell injury (Table
III) . Similar results were obtained when cells
were exposed to the immune complex (Table
IV) .
The concentrations of prostaglandins employed
were quite large . Although optimal results were
obtained with 2 .8 X 10-4 M concentrations,
PGE1 and PGA2 retarded hydrolase release
from phagocytes at concentrations as low as 2 .8 X
10-6 M (I µg/ml) (Table V) .
In initial experiments PGE 2 did not reduce
enzyme release . It has been demonstrated that
PGE2 reduces the deformability of red blood
cells and it has been suggested that erythrocytes
may be one of the primary receptors for PGE2
(22) . When contaminating erythrocytes were
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removed from cell suspensions by means of hypotonic lysis, the effect of PGE2 was comparable
to that of PGE t . The influence of erythrocytes
on the action of PGE 2 is documented in Table VI .
This effect of red blood cells was not observed
when cells were incubated with other prostaglandin compounds . In all experiments reported in
this paper, erythrocytes were removed by hypotonic lysis .

At the concentration used (10-1 M), colchicine
significantly retarded particle uptake by phagocytic cells whereas the cyclic nucleotides and
prostaglandin E and A compounds also depressed
C-1 glucose oxidation, a metabolic concomitant
of phagocytosis (Table VII) . This suggested that
reduced enzyme release might simply be a consequence of reduced particle uptake . Nonetheless,
the experiments did not exclude additional effects

TABLE III

Effect of 2 .8 X 10-4 M Prostaglandin and 10 -1 M Theophylline on Enzyme Release from
Human Leukocytes Exposed to Zymosan*
Percent of control enzyme release
Compound

No .

f -Glucuronidase

None (control)
Theophylline
PGEI
PGE1 + theophylline
PGE2
PGE2 + theophylline
PGA2
PGA2 + theophylline
PGFIO
PGF1s + theophylline
PGF2 .
PGF2a + theophylline

10
10
4
4
4
4
4
4
4
4
4
4

100 .0
68 .6 ± 3 .0$
67 .4 ± 7 .6$
46 .1 ± 3 .8$
59 .9 ± 4 .5$
48 .4 ± 5 .2$
43 .2 ± 6 .1$
39 .0 ± 3 .1$
88 .6 ± 1 .9
64 .7±2 .4$
135 .8 ± 5 .2$
125 .1 ± 4 .8$

Lactate dehydrogenase

100 .0
98 .4 ± 0 .4
97 .8 ± 1 .1
96 .9 ± 1 .0
99 .5 ± 1 .4
98 .7 ± 3 .0
100 .4 ± 0 .9
101 .8 ± 2 .1
100 .1 ± 1 .4
99 .7±0 .5
140 .4 ± 6 .2
131 .2 ± 4 .8

* Leukocytes (4 X 10 6) incubated with drug for 60 min at 37 °C, then exposed to zymosan for 60 min .
$ Significant at P < 0 .01 vs . control of 100% . (Control release = 22 .4 ± 2 .9% of
total (3-glucuronidase activity . See cells + zymosan Table I .)
TABLE IV

Effect of 2 .8 X 10-4 M Prostaglandin and 10-3 M Theophylline on Enzyme Release from
Human Leukocytes Exposed to Immune Complex*
Percent of control enzyme release
Compound

No.

None (control)
Theophylline
PGE1
PGEI + theophylline
PGA2
PGA2 + theophylline
PGFIO
PGFIO + theophylline
PGF2a
PGF2 . + theophylline

7
7
7
7
3
3
3
3
3
3

/3-Glucuronidase

100 .0
54 .9 ± 2 .1$
56 .3 ± 3 .4$
36 .2 ± 2 .9$
41 .4±4 .9$
32 .8 ± 5 .0$
87 .8±3 .1
54 .0 ± 3 .9$
127 .4 ± 4 .7$
119 .9 ± 4 .2$

Lactate dehydrogenase

100 .0
98 .3 ± 2 .0
97 .4 ± 1 .7
97 .2 ± 1 .5
101 .6±3 .7
101 .1 ± 0 .7
99 .4±1 .0
100 .7 ± 0 .8
139 .6 ± 6 .8
122 .9 ± 5 .1

* Leukocytes (4 X 10 6 ) incubated with drug for 60 min at 37 ° C, then exposed to
aIgG/IgM for 120 min,
$Significant at P < 0 .01 vs . control of 100% . (Control release = 14 .4 ± 1 .6 0]0 of
total 0-glucuronidase activity . See cells + aIgG/IgM Table II .)
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TABLE V

of these compounds on intracellular events subsequent to particle ingestion . Therefore, experiments were designed so that enzyme release
might be studied without concern for the engulfment phase of phagocytosis . Henson has demonstrated that the encounter between neutrophils
and immune complexes dispersed along a nonphagocytosable surface results in selective release
of lysosomal enzymes (4) . The technique was
adapted to our studies .

Inhibition of Enzyme Release from Human
Leukocytes*
-Glucuronidase

Compound

Concentration

Percent of total
release

Percent of
control
release

M

None
None
PGEI
PGE1
PGE1
PGA2
PGA2
PGA2

(Resting)
(Control)
2 .8 X 10- 4
2 .8 X 10-5
2 .8 X 10-6
2 .8 X 10-4
2 .8 X 10-5
2 .8 X 10-6

1 .9
23 .6
15 .5
18 .7
20 .4
9 .7
17 .7
19 .5

t
f
f
f
f
f
t
±

0 .7
2 .7
0 .4
0 .9
1 .9
1 .0
0 .7
2 .0

8 .1
65 .9$
77 .5$
83 .5§
41 .0$
73 .21
80 .8$

Cells Exposed to
Nonphagocytosable Stimuli
Human leukocytes were allowed to settle onto
Millipore filters (see Materials and Methods) and
incubated at 37 ° C for 2 h . Under these circumstances, in the absence of phagocytosis, there was
selective release of lysosomal enzymes . The kinetics of enzyme release are demonstrated in
Fig. 2 . Most enzyme release, as was the case in

* 1 h incubation with drug followed by 1 h incubation with zymosan particles .
$ P < 0 .01 vs . control of 1000]0 .
§ P < 0 .05 vs . control of 100% .

TABLE VI

Influence of Erythrocytes on Inhibition of Enzyme Release by PGE2 *
f3-Glucuronidase release
RBC

-RBC

Compound

Percent of total

Percent of
control

Percent of total

Percent of
control

None (resting)
None (control)
PGE2 (2 .8 X 10-4 M)

1 .7 t 1 .0
22 .8 t 2 .1
20 .5 f 0 .9

7 .5
89 .8

2 .1 f 0 .7
21 .7 t 1 .9
13 .0 f 1 .4

9 .7
59 .9

* 1 h incubation with PGE2 followed by 1 h incubation with PGE2 and zymosan .
Values are mean (± SEM) of three experiments .

TABLE VII

Glucose Oxidation in Human Polymorphs during Particle Uptake
Exposure of cells to aIgG/IgM complex
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Compound added

Concentration

Difference
resting vs .
phagocytic

M

cpm X 10-2

None
PGE1
Theophylline
PGE1 + theophylline
Colchicine

(Control)
2 .8 X 10-4
10-3
2 .8 X 10-4 + 10-3
10-3

96
48
61
24
28

THE JOURNAL OF CELL BIOLOGY . VOLUME 58, 1973

Percent
inhibition

00 .0
50 .0
36 .5
75 .0
70 .6

AMOUNT OF PROTEIN
ON SURFACE

U
Q
W W
QY
W N
J Z
WW
X J

1 0

Wa

f0
0
N
z W
0
W
IZ
W
U

5

W

a.

30

120

60

MINUTES

2 Selective enzyme release from human leukocytes . Kinetics of release and effect of immune
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TABLE VIII
Adherence of Immune Complex to Millipore Filters *
Complex added to filter
µg

25
100
200
400

Complex recovered

cpm

118
508
1346
1921

Percent recovery

cpm

(100-136)
(484-532)
(1280-1412)
(1804-2038)

127
497
1259
1788

(101-153)
(412-582)
(1199-1319)
(1704-1872)

107 .5
97 .7
93 .6
92 .8

Numbers represent mean (and range) of two experiments .
* Immune complex (125 1-labeled) applied to filters . Filters incubated with leukocytes
at 37 °C X 3 h . Filters washed . Counts made in Nuclear-Chicago Corp . Model 4216
Automatic Gamma Sample Counting System .
bulk phase experiments,

occurred

during the

first 60 min .
EVIDENCE THAT ENZYME RELEASE FROM
CELLS ON MILLIPORE FILTER WAS NOT DUE TO
UPTAKE OF COMPLEXES IN THE BULK PHASE :

It was important to determine that immune
complexes coated onto filters in fact remained
there, and that leukocytes added to the chamber
settled onto the filter . Recovery experiments
utilizing 1211-labeled y-globulin indicated that
only small amounts of the deposited complex
were removed from the filter during the course
of the experiment (Table VIII) . Generally,
6 X 10 5 cells were added to the chamber . At
the end of the experiment usually 2 X 10 5 cells

were recovered in the supernatant . Fluorescein
staining of the leukocytes failed to demonstrate
immune complexes within cells, indicating that
those cells which did remain in the bulk phase
had not engaged in phagocytosis . In addition,
amounts of immune complexes (e .g . 200 µg)
which, when dispersed along the filter, caused
significant release of /3-glucuronidase, did not
induce significant enzyme release when added
to cells in the bulk phase (Table IX) . When cells
were incubated with the dibutyryl analogue of
cAMP, with prostaglandin E and A compounds,
and with 10-5 M colchicine before being exposed
to immune complex on filters, there was reduction
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of induced enzyme release (Table X) . PGF I y
again failed to retard enzyme release .

ports particle uptake, C-1 oxidation, and enzyme

It has

are exposed to immune complexes or MSU crystals (11) . However, when cells were challenged

EFFECT OF SERUM INACTIVATION :

been shown that heat-inactivated serum sup-

release almost as well as fresh serum when cells

with zymosan, modest but significant increments
TABLE IX

in phagocytosis and its metabolic concomitants

Enzyme Release Induced by Immune Complex :
Bulk Phase versus Nonphagocytosable Surface*

were observed with fresh serum . The effect on
enzyme release of heat inactivation was also

Protein concentration

Percent of total 8-glucuronidase release

studied . The presence of complement components (fresh serum) augmented only modestly

Nonphagocytosable
surface

the release of lysosomal enzymes from cells which

Bulk phase

had encountered immune complexes on the Millipore filter (Table XI) . Despite the evidence

+Ag

0 (cells only)
50
100
200
400

2 .8
3 .0
3 .9
6 .1
14 .4

±
±
±
±
±

0 .6
0 .9
0 .8
1 .5
1 .6

3 .2
5 .7
6 .6
13 .3
16 .5

±
±
±
±
±

that phagocytosis of complexes does not occur

0 .8
1 .4
1 .2
1 .4
1 .7

in this system, it cannot be inferred that phagocytic vacuoles were not formed in neutrophils
adherent to the Millipore filter . Hawkins has
utilized ferritin-anti-ferritin complexes on the

* Leukocytes exposed to immune complex for 2
h at 37 0 C .
Values are mean (± SEM) of three experiments .

filters, and in electron micrographs has observed
phagosomes which contain clusters of ferritin (23) .
THE EFFECT OF INHIBITING PHAGOCYTOSIS

TABLE X
Inhibition of Enzyme Release from Human Leukocytes Exposed to Immune Complex on
Nonphagocytosable Surface*

Percent of control enzyme release
Compound

No.

O-Glucuronidase

LDH

None (control)
Dibutyryl cAMP 10 -3 M
PGEI 2 .8 X 10-4 M
Theophylline 10-3 M
2-Chloroadenosine 10-3 M
PGEI + theophylline
PGEI + 2-chloroadenosine
PGAI2 .8X 10-4 M
PGF1S2 .8X10-4 M
Colchicine 10-5 M

7
4
4
4
4
4
4
4
4
4

100 .0
75 .7 ± 2 .61
81 .3±1 .91
83 .1 ± 2 .4
73 .0 ± 1 .91
55 .9 ± 3 .31
62 .9 ± 2 .7t
64 .2±3 .11
90 .0± 1 .8
73 .3 ± 2 .9t

100 .0
99 .4 ± 1 .1
97 .8±0 .9
101 .4 ± 1 .7
97 .8 ± 2 .4
96 .6 ± 2 .9
99 .0 ± 1 .0
99 .1 ±0 .9
98 .9±0 .7
102 .5 ± 1 .9

Percent of total enzyme release¢

,B-Glucuronidase

Cells + filter (resting)
Cells + filter + complex
(control)

7
7

3 .2 ± 0 .8
16 .5 ± 1 .7

LDH

4 .0 ± 4 .4
4 .8 ± 3 .7

* Human leukocytes (6 X 10 6 ) exposed to aIgG/IgM complex (400 µg) for 2 h . at
37 ° C. Pretreatment with drugs : 1 h, 37 °C.
1 P < 0 .01 vs . control of 100% .
§ Enzyme activity expressed as a percentage of total activity released by 0 .2% Triton
X-100. Total activity (100%) of (3-glucuronidase was 24 .6 ± 1 .8 Ag phenolphthalein/
4 X 10 6 leukocyte/h ; lactate dehydrogenase (LDH) : 1640 ± 107 absorbancy units/
4 X 10 8 leukocyte .
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Cells Exposed to Membrane-Lytic Agents

TABLE XI
Effect of Serum Inactivation on Enzyme Release
from Nonphagocytosable Surface *
Percent of total ig-glucuronidase release

Surface + cells
Surface f aIgG/
RF + cells

Fresh serum

Heated serum

8 .4 f 0 .7
17 .7 t 1 .6

7 .7 t 1 .0
13 .1 f 1 .2

* Leukocytes exposed to surface for 2 h at 37 °C .
Values represent mean of three experiments .
BY MEANS OF CYTOCHALASIN B :

We there-

fore studied the morphological and biochemical
consequences of exposing leukocytes to nonphagocytosable particles . This was accomplished by
using cytochalasin B, a fungal metabolite known
to disrupt microfilaments and inhibit ingestion of
particles by human leukocytes (24-26) . Incubation of cells with 5 µg/ml cytochalasin B before
exposure of cells to zymosan resulted in complete
inhibition of zymosan uptake . Zymosan particles
adhered to the plasma membrane and induced
enzyme release but were not ingested (Fig. 3) .
Phagocytic vacuoles within neutrophils were not
seen on any of many electron microscope grids
observed ; enzyme appeared to be released directly
to the outside of the cell and, since treatment of
cells with cytochalasin B did not enhance enzyme
release (Table XII), this system converts the
regurgitation during feeding model into the reverse endocytosis model in which release of lysosomal enzyme is independent of particle uptake
and phagosome formation . It was therefore of
interest to study the effect on enzyme release of
colchicine and of agents which increase cAMP
concentration. Incubation of cells with 10-5 M
colchicine, 5 X 10-5 M vinblastine, or with dibutyryl cAMP and PGE, before treatment of
cells with cytochalasin B and exposure to zymosan
reduced extrusion of lysosomal enzymes (Table
XII) . As was the case for PGE1, the effect of
dibutyryl cAMP was dose dependent . Colchicine
and vinblastine were not inhibitory at lower
concentrations . There is apparently a threshold
concentration at which colchicine becomes maximally effective, as greater concentrations in
this system produced no further inhibitory effect
and 10- s M colchicine was needed to reduce
enzyme release in the bulk phase (Tables I and
II) .

Cell suspensions incubated with MSU crystals
release cytoplasmic as well as lysosomal enzymes,
with subsequent death of the cells (11) . However,
the kinetics of enzyme release from cells exposed
to the membrane-lytic detergent Triton X-100
differed from those observed after cells ingested
MSU crystals (Fig . 4) . In the first instance there
was rapid release of large proportions of total
enzyme whereas enzyme release was delayed in
the latter . In addition, incubation of cells with
MSU crystals resulted in normal increments of
C-1 oxidation (a metabolic consequence of phagocytosis) before enzyme release, whereas the addition of Triton X-100 prevented C-1 oxidation,
and led to immediate release of enzymes (Table
XIII) . It may therefore be inferred that enzyme
release follows phagocytosis of crystals and is due
to "perforation from within" rather than lysis
of plasma membrane by crystals in the media .
There is no evidence that agents which affect
the intracellular level of cyclic nucleotides prevent rupture of lysosomal membranes by MSU .
Were, however, merger of granules with phagocytic vacuoles to be impeded, or were phagocytosis inhibited, reduced release from cells of acid
hydrolase would be expected . Leukocytes were
therefore incubated with PGE I, PGF 10, and
dibutyryl cAMP before challenge by MSU
crystals . Dibutyryl cAMP and PGE I (but not
PGF 10) did in fact reduce release of lysosomal
enzymes (Table XIV), whereas such agents had
no effect on enzyme release from cells incubated
with Triton X-100 (Table XV) .
DISCUSSION

The release of enzymes from human leukocytes
is reduced when cells are pretreated with pharmacologic doses of agents which increase cellular
levels of cAMP or with compounds which disrupt microtubule integrity under three experimental circumstances : (a) phagocytosis of particles from the bulk phase, (b) encounter with
nonphagocytosable particles, (c) exposure to
crystals of MSU. In contrast, enzyme release from
cells incubated with the detergent Triton X-100
was not prevented when cells were preincubated
with such agents . These observations indicate
that such compounds affect an intracellular event
subsequent to particle encounter and/or ingestion .
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a Portions of two human peripheral blood neutrophils treated with cytochalasin B and then
fixed and stained for peroxidase by the method of Graham and Karnovsky (13) . Many peroxidase-positive
lysosomes are seen at the cell periphery . Line indicates 0 .5 µm. X 28,000.
FIGURE 3

3 b A portion of a human peripheral blood neutrophil treated with cytochalasin B and then
exposed to zymosan (zym) (60 min) . Peroxidase-positive material is seen emerging from a lysosome that
has fused with the cell membrane (arrow) . At the left are other peroxidase-positive deposits in lysosomes
that are open to the outside of the cell (double arrows) . Line indicates 0.5 µm . X 46,000.
FIGURE

38

TABLE XII

Enzyme Release from Human Leukocytes Treated with Cytochalasin B*
Enzyme activity released into supernatant$
Percent
y-glucuronidase

Compounds added

None (resting)
Cytochalasin B (CB) 5 µg/ml
CB + zymosan (control)
Dibutyryl cAMP 10-3 M +
CB + zymosan
PGE1 2 .8 X 10-4 M + theophylline 10-3 + CB +
zymosan
Colchicine 10-5 M + CB +
zymosan
Vinblastine 5 X 10-5 M +
CB + zymosan

5 .8
6 .4
32 .6
19 .7

t
t
f
±

2 .4
2 .9
3 .4
2 .6

Percent lactate
dehydrogenase

3 .7
4 .5
5 .1
5 .0

t
t
f
f

Percent of control
y-glucuronidase release

0 .9
1 .0
1 .2
0 .9

100 .0
60 .4 f 3 .7 §

17 .8 f 2 .0

4 .0 f 1 .0

54 .3 f 4 .1 §

22 .8 f 3 .1

4 .6 f 1 .3

70 .0 t 6 .7§

20 .9 f 2 .7

5 .2 t 2 .9

64 .2 f 5 .8§

* Leukocytes (4 X 10 6 ) incubated with drug for 60 min at 37 ° C, then with CB for 15
min, then exposed to zymosan for 60 min .
$ Enzyme activity expressed as a percentage of total activity (4 X 10 6 leukocytes)
released by 0 .2% Triton X-100 . Total activity (1007) of (3-glucuronidase was 20.6 t
2 .8 µg phenolphthalein/4 X 10 leukocyte/h ; lactate dehydrogenase : 1420 f 77 absorbancy units/4 X 10 6 leukocyte .
§ Significant at P < 0 .01 vs . control of 100% (No . = 4) .
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FIGURE 4 Enzyme release from leukocytes. Leukocytes challenged with MSU crystals (0 .1 mg/ml)
and Triton X-100 (0 .5% vol/vol) .

Intracellular movements of lysosomes, and of
secretory granules in a variety of cell types, appear to be accomplished by an interaction between cyclic nucleotides, microtubules, and micro-

filaments . In order for degranulation and enzyme
release to proceed in response to perturbation
of the cell membrane, microtubules must remain
under appropriate controls . Although micro-
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TABLE XIII

tubules are in a dynamic state of assembly and

Effect of Triton X-100 on Phagocytosis*

disassembly, it is probably in their aggregated

Cl-glucose
oxidation

no .

state that microtubules exert their influence on
cell mechanics (27) . cAMP and colchicine both
favor disassembly of microtubules (28) and both
reduce selective enzyme release . cAMP and

`¢m̀

Control (resting)
Cells + MSU
Cells + MSU + Triton X-100

3
3
3

1387 f 202
5711 f 501
1519 f 317

compounds which increase its cellular concentration also reduce antigen-induced histamine release from sensitized leukocytes and lung tissue

* Human leukocytes (2 X 10 6) exposed to MSU or (29, 30) . In contrast, deuterium oxide (D 20)
MSU + Triton X-100 for 60 min, 37°C .
favors formation of microtubules (31) and augTABLE XIV

Inhibition of Enzyme Release from Human Leukocytes Exposed to Monosodium Urate
Crystals*
Percent of control enzyme release
Compound with concentration

No .

#-Glucuronidase

6
4
4
4

100 .0
58 .6 f 4 .7t
68 .2 f 5 .4 :
97 .0 ± 3 .1

None (control)
Dibutyryl cAMP 10 -3 M
PGE1 2 .8 X 10 - 'M
PGF1o 2 .8 X 10 -4 M

Lactate dehydrogenase

100 .0
67 .1 f 3 .0t
70 .9 t 1 .9t
100 .0 t 2 .6

Enzyme release (percent of total activity)§

Resting cells
Cells + MSU (control)

6
6

4 .5 t 1 .1
21 .0 t 1 .9

3 .1 t 0 .9
25 .6 f 2 .3

* Leukocytes (4 X 10 6 ) incubated with drugs at 37 °C for 1 h, then exposed to MSU
(0 .1 mg/ml) for 1 h .

I P < 0.01 vs . control of 100% .
§ Enzyme activity expressed as a percentage of total activity released by 0 .2% Triton
X-100 . Total activity (100%) of 0-glucuronidase was 18 .1 f 1 .0 pg phenolphthalein/
4 X 10 6 leukocyte/h ; lactate dehydrogenase : 1176 t 78 absorbancy units/4 X 10 6
leukocyte .
TABLE XV

Enzyme Release from Human Leukocytes Exposed to Triton X-100*
Percent of control enzyme release
Compound and concentration

No .

t3-Glucuronidase

Lactate dehydrogenase

None (control)
PGE1 2 .8 X 10 -4 M
Dibutyryl cAMP 10 -3 M
Colchicine 10 -3 M

3
3
3

100 .0
105 .1 t 1 .8
103 .3 t 2 .4
91 .4 t 4 .1

100 .0
101 .9 ± 0 .7
105 .2 t 1 .9
97 .4 f 2 .3

3

Enzyme release (percent of total activity) j

Resting cells
Cells + Triton X-100

3
3

3 .4 f 1 .6
33 .9 t 4 .1

3 .3 f 2 .7
36 .7 f 3 .2

* Leukocytes (4 X 10 6 ) incubated with drugs at 37 ° C for 1 h, then exposed to Triton
X-100 (0 .05% vol/vol) for 15 min .
t Enzyme activity expressed as a percentage of total activity released by 0 .2% Triton
X-100 . Values are means of three experiments . Total activity (100%) of //3-glucuronidase was 16 .8 t 1 .7 pg phenolphthalein/4 X 10 6 leukocyte/h, lactate dehydrogenase :
1060 t 94 absorbancy units/4 X 10 6 leukocyte .
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ments

histamine release from leukocytes (32) .
In addition, it has recently been reported that
,8-adrenergic agents
levels)

reduce,

(which

whereas

increase

cholinergic

sAMP
agonists

enhance, lysosomal enzyme release from leukocytes (33), and immunologic release of histamine
and SRS-AI from human lung fragments

(34) .

Cholinergic stimulation of heart and brain preparations has produced an increase in levels

of

cyclic guanosine 3'S'-monophosphate (cGMP)
(35),

and the introduction of 8-bromo-cGMP

to sensitized lung tissue (34) and of cGMP to
leukocyte suspensions (33) was associated with
enhancement of antigen-induced release of histamine and SRS-A in the first instance and enhancement of lysosomal enzyme release in the
latter circumstance . Thus, it appears that in
human leukocytes granule movement and acid
hydrolase release may be modulated through
changes in concentrations of at least two cyclic
nucleotides, sAMP and cGMP . It is therefore
possible that the release

of inflammatory sub-

stances from phagocytes can be controlled by
humoral means and that many

of these may

affect microtubule function .
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